Equity Profile

INSM

Insmed Incorporated

Health CareBiotechnology$27.6B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Insmed Incorporated is a biotechnology company focused on developing innovative therapies for patients with serious and rare diseases. Operating in the health care sector, Insmed's work is crucial as it addresses unmet medical needs, particularly in the treatment of conditions like pulmonary infections.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and investor sentiment.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and validate its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

INSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-22.08%

Avg Stock Reaction

-1.20%

Last Quarter Recap

In Q1-2026, Insmed reported an EPS of -$0.76, which was better than the expected -$0.90, resulting in a positive surprise. However, the stock reacted negatively, dropping 23.41% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as Insmed has a history of both beating and missing earnings estimates. Investors are particularly focused on the company's ability to manage costs and drive revenue growth.

Bull Case

If Insmed can demonstrate strong revenue growth and improved margins, it could signal a turnaround and attract more investor interest, leading to a potential stock price increase.

Bear Case

Conversely, if the company fails to show progress in its revenue or continues to post significant losses, it could lead to further declines in stock price and investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue figures can Insmed provide for its key products this quarter?

Revenue figures will be critical in assessing the company's market traction and growth potential, especially after previous earnings misses.

How is Insmed managing its expenses in light of ongoing losses?

Cost management will be essential for improving profitability and investor confidence, particularly given the company's history of significant EPS misses.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Insmed's potential for revenue growth from its key therapies, especially given recent positive data from clinical trials.

Supporting Evidence

The options market is pricing in a significant move, indicating that investors expect volatility, which could be due to positive developments not yet reflected in consensus estimates.

Insmed's recent EPS surprise shows that it can outperform expectations, suggesting that the market may be overly cautious.

Key Risk

If Insmed reports revenue growth that exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Insmed's ability to turn around its financial performance and manage costs effectively.

Bull Confirmed If

Demonstrating revenue growth of at least 15% quarter-over-quarter would confirm the bull case.

Bear Confirmed If

If revenue declines or does not meet expectations, it would reinforce the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.56%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±21.6% while INSM has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

92.2%

Calls (408K)P/C Ratio: 1.13Puts (123K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insmed beats expectations, history suggests a potential stock increase of around 16.33%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience muted movement as investors weigh future guidance.

Miss

If Insmed misses expectations, history suggests a potential decline of about 1.98%, leading to increased concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on revenue growth from key product lines.
2Details on cost management strategies and their impact on profitability.
3Any new partnerships or collaborations that could enhance market reach.
4Insights into ongoing clinical trials and their expected timelines.
5Management's outlook on market conditions and competitive landscape.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and investor sentiment.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and validate its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

INSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-22.08%

Avg Stock Reaction

-1.20%

Last Quarter Recap

In Q1-2026, Insmed reported an EPS of -$0.76, which was better than the expected -$0.90, resulting in a positive surprise. However, the stock reacted negatively, dropping 23.41% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Insmed can demonstrate strong revenue growth and improved margins, it could signal a turnaround and attract more investor interest, leading to a potential stock price increase.

Bear Case

Conversely, if the company fails to show progress in its revenue or continues to post significant losses, it could lead to further declines in stock price and investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue figures can Insmed provide for its key products this quarter?

Revenue figures will be critical in assessing the company's market traction and growth potential, especially after previous earnings misses.

How is Insmed managing its expenses in light of ongoing losses?

Cost management will be essential for improving profitability and investor confidence, particularly given the company's history of significant EPS misses.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Insmed's potential for revenue growth from its key therapies, especially given recent positive data from clinical trials.

Supporting Evidence

The options market is pricing in a significant move, indicating that investors expect volatility, which could be due to positive developments not yet reflected in consensus estimates.

Insmed's recent EPS surprise shows that it can outperform expectations, suggesting that the market may be overly cautious.

Key Risk

If Insmed reports revenue growth that exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Insmed's ability to turn around its financial performance and manage costs effectively.

Bull Confirmed If

Demonstrating revenue growth of at least 15% quarter-over-quarter would confirm the bull case.

Bear Confirmed If

If revenue declines or does not meet expectations, it would reinforce the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.56%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±21.6% while INSM has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

92.2%

Calls (408K)P/C Ratio: 1.13Puts (123K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insmed beats expectations, history suggests a potential stock increase of around 16.33%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience muted movement as investors weigh future guidance.

Miss

If Insmed misses expectations, history suggests a potential decline of about 1.98%, leading to increased concerns about its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on revenue growth from key product lines.
2Details on cost management strategies and their impact on profitability.
3Any new partnerships or collaborations that could enhance market reach.
4Insights into ongoing clinical trials and their expected timelines.
5Management's outlook on market conditions and competitive landscape.